Resistant forms of breast cancer that over-expresses EGFR and HER2/neu often are less vulnerable to the cytotoxic properties of chemotherapeutics due to simultaneous over-expression of transmembrane P-glycoprotein[142–147]. This evidence concerns the gene EGFR and breast carcinoma.